Follow The Filings

CRSP position history

The shares of Crispr Therapeutics (CRSP) that ARK Investment Management LLC reported in each quarter’s 13F.

Equity, NAMEN AKT

Shares held by quarter

New Add Reduce Exit

  1. 2021 Q3: 7,585,674 shares, $849M, 2.0% of portfolio
  2. 2021 Q4: 9,087,868 shares, $689M, 2.1% of portfolio, Add +19.8%
  3. 2022 Q1: 9,404,071 shares, $590M, 2.5% of portfolio, Add +3.5%
  4. 2022 Q2: 9,727,531 shares, $565M, 3.3% of portfolio, Add +3.4%
  5. 2022 Q3: 8,237,122 shares, $538M, 3.8% of portfolio, Reduce −15.3%
  6. 2022 Q4: 7,829,932 shares, $318M, 2.8% of portfolio, Reduce −4.9%
  7. 2023 Q1: 7,990,188 shares, $361M, 2.5% of portfolio, Add +2.0%
  8. 2023 Q2: 7,338,447 shares, $412M, 2.7% of portfolio, Reduce −8.2%
  9. 2023 Q3: 7,163,118 shares, $325M, 2.5% of portfolio, Reduce −2.4%
  10. 2023 Q4: 8,536,104 shares, $534M, 3.2% of portfolio, Add +19.2%
  11. 2024 Q1: 8,157,028 shares, $556M, 3.8% of portfolio, Reduce −4.4%
  12. 2024 Q2: 7,778,536 shares, $420M, 3.7% of portfolio, Reduce −4.6%
  13. 2024 Q3: 7,498,625 shares, $352M, 3.2% of portfolio, Reduce −3.6%
  14. 2024 Q4: 8,973,064 shares, $353M, 2.9% of portfolio, Add +19.7%
  15. 2025 Q1: 10,165,400 shares, $346M, 3.5% of portfolio, Add +13.3%
  16. 2025 Q2: 10,182,590 shares, $495M, 3.6% of portfolio, Add +0.2%
  17. 2025 Q3: 9,786,973 shares, $634M, 3.8% of portfolio, Reduce −3.9%
  18. 2025 Q4: 10,522,057 shares, $552M, 3.7% of portfolio, Add +7.5%
  19. 2026 Q1: 11,313,623 shares, $538M, 4.2% of portfolio, Add +7.5%
  20. 2026 Q2: 9,460,939 shares, $516M, 3.4% of portfolio, Reduce −16.4%
Holdings date Value % of holdings Shares Filing date All 13F holders